SCHEMBL161342

SCHEMBL161342

CCOC(C)I

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18291441 1.00
SCHEMBL7517602 0.76
SCHEMBL3159028 0.74 LMNA (0.32)
SCHEMBL28632794 0.74
SCHEMBL31296254 0.74 THRB (0.50)
SCHEMBL19711171 0.74
SCHEMBL27730330 0.73
SCHEMBL14434966 0.73
SCHEMBL16742365 0.72 ALDH1A1 (0.36)
SCHEMBL2094168 0.69 LMNA (1.00)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1572 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0955291-B1 Preparation of 2-substituted pyridines DOW AGROSCIENCES LLC (US) 2002-07-10 EP claimed
US-6054583-A Preparation of 2-substituted pyridines ROHM AND HAAS COMPANY (US) 2000-04-25 US claimed
EP-0955291-A1 Preparation of 2-substituted pyridines ROHM AND HAAS COMPANY (US) 1999-11-10 EP claimed
EP-0826739-A1 Process for the preparation of substituted aminoanthraquinones BAYER AG (DE) 1998-03-04 EP claimed
US-12037355-B2 Triterpene saponin analogues ADJUVANCE TECHNOLOGIES, INC. (US) 2024-07-16 US disclosed
WO-2024148274-A1 COMPLEMENT INHIBITION APELLIS PHARMACEUTICALS, INC. (US) 2024-07-11 WO disclosed
WO-2024147060-A1 NOVEL IONIZABLE LIPID COMPOUNDS FOR NUCLEIC ACID DELIVERY CELON PHARMA S.A. (PL) 2024-07-11 WO disclosed
EP-4396354-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF Wave Life Sciences Ltd. (SG) 2024-07-10 EP disclosed
WO-2024145435-A2 LIPID COMPOSITIONS AND METHODS FOR DELIVERY TO IMMUNE CELLS Life Technologies Corporation (US) 2024-07-04 WO disclosed
WO-2024140431-A1 COMPOUNDS COMPRISING HETEROARYL RINGS AND COMPOSITIONS AND METHODS THEREOF IONGEN THERAPEUTICS CO., LTD. (CN) 2024-07-04 WO disclosed
WO-2024130217-A1 STAPLED PEPTIDES AND METHODS THEREOF FOG PHARMACEUTICALS, INC. (US) 2024-06-20 WO disclosed
WO-2024130218-A1 STAPLED PEPTIDES AND METHODS THEREOF FOG PHARMACEUTICALS, INC. (US) 2024-06-20 WO disclosed
US-5594006-A SUCH AS COLLEGENASE, STROMELYSIN; ANTICANCER AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1997-01-14 US disclosed
WO-1996026933-A1 NOVEL SELECTIVE INHIBITORS OF VIRAL OR BACTERIAL NEURAMINIDASES GILEAD SCIENCES, INC. (US) 1996-09-06 WO disclosed
WO-1996023801-A2 NOVEL COMPOUNDS AND METHODS FOR MAKING AND USING SAME GILEAD SCIENCES, INC. (US) 1996-08-08 WO disclosed
WO-1996014314-A2 THIEPANE COMPOUNDS INHIBITING AND DETECTING HIV PROTEASE GILEAD SCIENCES, INC. (US) 1996-05-17 WO disclosed
EP-0368750-B1 Process for preparing substituted aminoanthraquinones SUMITOMO CHEMICAL CO (JP) 1994-10-26 EP disclosed
US-5017713-A Alkylation SUMITOMO CHEMICAL COMPANY, LTD. (JP) 1991-05-21 US disclosed
EP-0368750-A2 Process for preparing substituted aminoanthraquinones SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1990-05-16 EP disclosed
US-4560447-A Electrolytic process for preparation of α-alkylated acetic acid derivatives OTSUKA KAGAKU KABUSHIKI KAISHA (JP) 1985-12-24 US disclosed